Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer

JAMA

Volumn 280, Issue 11, 1998, Pages 975-980

  Albertsen, Peter C ^a   Hanley, James A ^a   Gleason, Donald F ^b   Barry, Michael J ^c  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK ASSESSMENT; SCORING SYSTEM;

EID: 0032537993     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.11.975     Document Type: Article

References (22)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin. 1998;48:6-29.
2. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer: a prospective, population-based study in Sweden. JAMA. 1997;277:467-471.
3. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994;330: 242-248.
4. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA. 1995;274:626-631.
5. Walsh PC, Brooks JD. The Swedish prostate cancer paradox. JAMA. 1997;277:497-198.
6. Swanson G. Survival and conservative treatment for localized prostate cancer [letter]. JAMA. 1996; 275:31.
7. Cowen ME, Kattan MW, Mües BJ. Survival and conservative treatment for localized prostate cancer [letter]. JAMA. 1996;275:31.
8. Bagshaw MA, Cox RS, Hancock SL. Control of prostate cancer with radiotherapy: long term results. J Ural. 1994;152:1781-1785.
9. Gerber GS, Thisted RA, Scardino PT, et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA. 1996;276: 615-619.
10. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy. Am J Surg Pathol. 1996;20586-292.
11. Blasko JC, Ragde H, Luse RW, Sylvester JE, Cavanagh W, Grimm PD. Should brachytherapy be considered a therapeutic option in localized prostate cancer? Urol Clin North Am. 1996;23:633-647.
12. Gleason DF. Histologie grading and clinical staging of carcinoma of the prostate. In: Tannenbaum M, éd. Urologie Pathology. Philadelphia, Pa: Lea & Febiger; 1977:171-198.
13. Charlson ME, Pompei P, Alex KL, MacKenzi CR. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. / Chronic Dis. 1987;40:373-383.
14. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons Inc; 1980:168-717.
15. Bishop YMM, Fienberg SE, Holland PW. Discrete Multivariate Analysis: Theory and Practice. Cambridge, Mass: MIT Press; 1975:123.
16. Stenbaek M, Rosen M. Cancer survival in Sweden in 1961-1991. Acta Oncol. 1995;34:62-63.
17. Aus G, Hugosson J, Norlen L. Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol. 1995;154:460-465.
18. Hugosson J, Aus G, Bergdahl C, Bergdahl S. Prostate cancer mortality in patients surviving more than 10 years after diagnosis. / Urol. 1995; 1545115-2117.
19. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995; 273589-294.
20. Murphy GP, Natarajan N, Pontes JE, et al. The national survey of prostate cancer in the United States by the Amercian College of Surgeons. J Urol. 1982;127:928-934.
21. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948-954.
22. Crawford ED, E isenberger M A, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide hi prostatic adenocarcinoma. N Engl J Med. 1989;321:419-424.